Brief: Hutchmed Announces Licensing Agreement With GSK For Kras-Egfr-Antibody Conjugate Cancer Therapy
03/09/2026 05:05
BRIEF-Hutchmed Announces Licensing Agreement With GSK For Kras-Egfr-Antibody Conjugate Cancer Therapy Sept 3 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
HUTCHMED ANNOUNCES LICENSING AGREEMENT WITH GSK FOR KRAS-EGFR-ANTIBODY CONJUGATE CANCER THERAPY
HUTCHMED (CHINA) - AGREEMENT INCLUDES $110 MILLION UPFRONT, UP TO $1.30 BILLION IN MILESTONES, PLUS ROYALTIES
Source text: ID:nGNX9KhmsX
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation